Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan ; volume:150 ; number:4 ; day:9 ; month:4 ; year:2024 ; pages:1-9 ; date:4.2024
Journal of cancer research and clinical oncology ; 150, Heft 4 (9.4.2024), 1-9, 4.2024

Creator
Hirasawa, Yosuke
Adachi, Takahiro
Hashimoto, Takeshi
Fukuokaya, Wataru
Koike, Yuhei
Yata, Yuji
Komura, Kazumasa
Uchimoto, Taizo
Tsujino, Takuya
Nishimura, Kazuki
Takahara, Kiyoshi
Saruta, Masanobu
Fujita, Kazutoshi
Hashimoto, Mamoru
Uemura, Hirotsugu
Shiroki, Ryoichi
Azuma, Takashi
Kimura, Takahiro
Ohno, Yoshio
Contributor
SpringerLink (Online service)

DOI
10.1007/s00432-024-05717-2
URN
urn:nbn:de:101:1-2408020909057.099835734277
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:55 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Hirasawa, Yosuke
  • Adachi, Takahiro
  • Hashimoto, Takeshi
  • Fukuokaya, Wataru
  • Koike, Yuhei
  • Yata, Yuji
  • Komura, Kazumasa
  • Uchimoto, Taizo
  • Tsujino, Takuya
  • Nishimura, Kazuki
  • Takahara, Kiyoshi
  • Saruta, Masanobu
  • Fujita, Kazutoshi
  • Hashimoto, Mamoru
  • Uemura, Hirotsugu
  • Shiroki, Ryoichi
  • Azuma, Takashi
  • Kimura, Takahiro
  • Ohno, Yoshio
  • SpringerLink (Online service)

Other Objects (12)

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma

Enfortumab Vedotin (Urothelkarzinom, Erstlinientherapie, Kombination mit Pembrolizumab) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung

Enfortumab Vedotin (Urothelkarzinom, Erstlinientherapie, Kombination mit Pembrolizumab) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung

Pembrolizumab (Urothelkarzinom, Erstlinientherapie, Kombination mit Enfortumab Vedotin) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung

Pembrolizumab (Urothelkarzinom, Erstlinientherapie, Kombination mit Enfortumab Vedotin) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer

A blood-based immune marker for resistance to pembrolizumab in patients with metastatic urothelial cancer

Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review

Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review

Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma

Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma

Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study

Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study

Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study

Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study

Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study

Related objects